insights_auto
Zašto je FARN pao 4,11%?
Istražite detaljnijechevron_right
FARN:LON
Faron Pharmaceuticals Oy
35,00 GBX
arrow_downward
−4,11%(−1,50) 1D
9. lis, 16:30:00 GMT+1 · GBX
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za FARN...
Otvori
35,00 GBX
Najviša
38,00 GBX
Najniža
35,00 GBX
Trž. kap.
73,96 mil.
Prosj. kol.
45,22 tis.
Količina
15,60 tis.
52-tjed. najviša
193,58 GBX
52-tjed. najniža
34,00 GBX
EPS
−0,10 GBX
Dionice u optjecaju
31,03 mil.
Broj djelatnika
36
Otvori
35,00 GBX
Najviša
38,00 GBX
Najniža
35,00 GBX
Trž. kap.
73,96 mil.
Prosj. kol.
45,22 tis.
Količina
15,60 tis.
52-tjed. najviša
193,58 GBX
52-tjed. najniža
34,00 GBX
EPS
−0,10 GBX
Dionice u optjecaju
31,03 mil.
Broj djelatnika
36
Vijesti
Iz web-izvora i od partnera za vijesti
hr.bloombergadria.com
·
prije 2 dana
Trump slavi rekorde na Wall Streetu, ali iza burzovne euforije krije se opasna istina
StreetInsider
·
prije 25 minuta
XRP News Today: Nasdaq Exposure Could Transform XRP as Remittix Targets Everyday Payment Adoption
Mitrade
·
prije 9 minuta
XRP’s Nasdaq Moment Nears: 5 Things to Know About Evernorth
Bloomberg.com
·
prije 3 sata
Oil Rises on Mideast Attacks, Dollar Edges Higher: Markets Wrap
Profil
Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland.
The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy.
Its lead product Traumakine has been developed to treat acute respiratory distress syndrome. It is currently undergoing international phase III clinical trials after an open-label, early-phase trial showed promising results in the treatment patients with ARDS. The drug is known to function by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine, such that vascular leaking and escalation of inflammation are reduced. The U.S. Food and Drug Administration FDA has accepted the proposed protocol design for the next Traumakine study in March 2020. The phase III study is a comparison of efficacy in the treatment of patients with ARDS.
In 2020 Traumakine was selected to take part in the WHO Solidarity trial and REMAP-CAP trials to find drugs for the symptoms of Covid_19. Wikipedia
Faron Pharmaceuticals Oy – informacije
Glavni izvršni direktorMarkku Jalkanen
Zaposlenici36
Osnovano2003
Sjedište-
Sektor-
Web-lokacijafaron.com